儿童噬血性淋巴组织细胞增多症诊治进展

魏昂; 王天有

doi:10.13201/j.issn.1004-2806.2022.01.002

儿童噬血性淋巴组织细胞增多症诊治进展

魏昂¹,
王天有^1, ,

- 国家儿童医学中心，首都医科大学附属北京儿童医院，血液肿瘤中心，儿童血液病与肿瘤分子分型北京市重点实验室，儿科学国家重点学科，儿科重大疾病研究教育部重点实验室(北京，100045)
基金项目:
国家科技重大专项(No：2017ZX09304029001)；北京市科技委员会首都临床特色应用研究与成果推广(No：Z171100001017050)；首都卫生发展科研专项研究重点公关项目(No：2020-1-2022)；国家自然科学基金(No：82070202)

详细信息

作者简介:
专家简介：王天有，首都医科大学附属北京儿童医院血液病中心主任、主任医师、博士生导师。担任中华医学会儿科学分会主任委员，中华医学会理事，中国医师协会儿科分会副会长，中国医疗保健国际交流促进会儿科医学分会主任委员等。《中华儿科杂志》主编、《中国小儿血液与肿瘤杂志》主编，《北京医学杂志》、《中国小儿急救杂志》、《中国小儿循证医学杂志》、《中国实用儿科杂志》副主编。中华人民共和国国务院授予“政府特殊津贴”获得者，被人民网健康时报授予“国之名医卓越建树”荣誉

通讯作者: 王天有，E-mail：wangtianyou@bch.com.cn

中图分类号: R725.5

收稿日期: 2021-11-02

刊出日期: 2022-01-01

Progress in diagnosis and treatment of hemophagocytic lymphohistiocytosis in children

WEI Ang¹,
WANG Tianyou^1, ,

More Information

Corresponding author: WANG Tianyou, E-mail: wangtianyou@bch.com.cn

Received Date: 02 November 2021

Publish Date: 01 January 2022

摘要

- 噬血性淋巴组织细胞增多症 /
- 儿童 /
- 诊断 /
- 治疗
- hemophagocytic lymphohistiocytosis /
- children /
- diagnosis /
- treatment

HTML全文

参考文献(45)

[1]	McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders[J]. Nat Rev Dis Primers, 2021, 7(1): 73. doi: 10.1038/s41572-021-00307-9
[2]	Cleves D, Lotero V, Medina D, et al. Pediatric hemophagocytic lymphohistiocytosis: A rarely diagnosed entity in a developing country[J]. BMC Pediatr, 2021, 21(1): 411. doi: 10.1186/s12887-021-02879-7
[3]	Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol[J]. Blood, 2011, 118(17): 4577-4584. doi: 10.1182/blood-2011-06-356261
[4]	Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis[J]. Annu Rev Pathol, 2018, 13: 27-49. doi: 10.1146/annurev-pathol-020117-043625
[5]	Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy[J]. Best Pract Res Clin Rheumatol, 2020, 34(4): 101515. doi: 10.1016/j.berh.2020.101515
[6]	Ishii E. Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment[J]. Front Pediatr, 2016, 4: 47.
[7]	Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic Lymphohistiocytosis[J]. Arch Pathol Lab Med, 2021 Aug 4. doi: 10.5858/arpa.2020-0802-RA.Onlineaheadofprint.
[8]	Athale J. Challenges in Identifying Hemophagocytic Lymphohistiocytosis in the ICU[J]. Crit Care Med, 2020, 48(4): 599-600. doi: 10.1097/CCM.0000000000004257
[9]	Meena NK, Sinokrot O, Duggal A, et al. The Performance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis in Critically Ill Patients[J]. J Intensive Care Med, 2020, 35(12): 1476-1482. doi: 10.1177/0885066619837139
[10]	Lachmann G, Knaak C, Vorderwülbecke G, et al. Hyperferritinemia in Critically Ill Patients[J]. Crit Care Med, 2020, 48(4): 459-465. doi: 10.1097/CCM.0000000000004131
[11]	Gregory J, Greenberg J, Basu S. Outcomes Analysis of Children Diagnosed With Hemophagocytic Lymphohistiocytosis in the PICU[J]. Pediatr Crit Care Med, 2019, 20(4): e185-e190. doi: 10.1097/PCC.0000000000001827
[12]	Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase Ⅱ clinical trial on the safety and efficacy of tadekinig alfa(IL-18BP)in adult-onset Still's disease[J]. Ann Rheum Dis, 2018, 77(6): 840-847.
[13]	Shimizu M, Inoue N, Mizuta M, et al. Characteristic elevation of soluble TNF receptor Ⅱ: I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis[J]. Clin Exp Immunol, 2018, 191(3): 349-355. doi: 10.1111/cei.13026
[14]	Gao Z, Wang Y, Wang J, et al. Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome[J]. Mediterr J Hematol Infect Dis, 2019, 11(1): e2019008.
[15]	Madkaikar M, Shabrish S, Desai M. Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis(HLH)[J]. Indian J Pediatr, 2016, 83(5): 434-443. doi: 10.1007/s12098-016-2037-y
[16]	Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study[J]. Blood, 2017, 130(25): 2728-2738. doi: 10.1182/blood-2017-06-788349
[17]	Bergsten E, Horne A, Myrberg IH, et al. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study[J]. Blood Adv, 2020, 4(15): 3754-3766. doi: 10.1182/bloodadvances.2020002101
[18]	Rosée PL, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23): 2465-2477. doi: 10.1182/blood.2018894618
[19]	Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis(EBV-HLH); update 2010[J]. J Pediatr Hematol Oncol, 2011, 33(1): 35-39. doi: 10.1097/MPH.0b013e3181f84a52
[20]	Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2015, 126(19): 2186-2192. doi: 10.1182/blood-2015-05-644914
[21]	Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Hematol Oncol, 2016, 9(1): 84. doi: 10.1186/s13045-016-0317-7
[22]	Zhao Y, Li Z, Zhang L, et al. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis[J]. Br J Haematol, 2020, 191(3): 453-459. doi: 10.1111/bjh.16861
[23]	Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis[J]. Blood Adv, 2017, 1(19): 1533-1536. doi: 10.1182/bloodadvances.2017007526
[24]	魏昂, 张蕊, 王天有. JAK-STAT通路与噬血细胞综合征[J]. 国际儿科学杂志, 2019, 46(8): 566-570. doi: 10.3760/cma.j.issn.1673-4408.2019.08.007
[25]	Wei A, Ma H, Li Z, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children[J]. Int J Hematol, 2020, 112(4): 568-576. doi: 10.1007/s12185-020-02936-4
[26]	Zhang Q, Wei A, Ma HH, et al. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis[J]. Haematologica, 2021, 106(7): 1892-1901.
[27]	Chatterjee B, Deng Y, Holler A, et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo[J]. PLoS Pathog, 2019, 15(5): e1007748. doi: 10.1371/journal.ppat.1007748
[28]	Kim SJ, Hyeon J, Cho I, et al. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas[J]. Cancer Res Treat, 2019, 51(2): 611-622. doi: 10.4143/crt.2018.191
[29]	El-Mallawany NK, McClain KL. Checkmate for EBV-HLH[J]. Blood, 2020, 135(11): 782-784. doi: 10.1182/blood.2020005041
[30]	Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2020, 135(11): 826-833. doi: 10.1182/blood.2019003886
[31]	Shamriz O, Kumar D, Shim J, et al. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis(HLH)Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH[J]. J Clin Immunol, 2021, 41(7): 1582-1596. doi: 10.1007/s10875-021-01073-9
[32]	Lounder DT, Bin Q, de Min C, et al. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections[J]. Blood Adv, 2019, 3(1): 47-50. doi: 10.1182/bloodadvances.2018025858
[33]	Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis[J]. N Engl J Med, 2020, 382(19): 1811-1822. doi: 10.1056/NEJMoa1911326
[34]	Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society[J]. J Allergy Clin Immunol Pract, 2018, 6(5): 1508-1517. doi: 10.1016/j.jaip.2018.05.031
[35]	Horne A, Wickström R, Jordan MB, et al. How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?[J]. Curr Treat Options Neurol, 2017, 19(1): 3. doi: 10.1007/s11940-017-0439-4
[36]	Messina C, Zecca M, Fagioli F, et al. Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy[J]. Biol Blood Marrow Transplant, 2018, 24(6): 1223-1231. doi: 10.1016/j.bbmt.2018.01.022
[37]	Allen CE, Marsh R, Dawson P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies[J]. Blood, 2018, 132(13): 1438-1451. doi: 10.1182/blood-2018-01-828277
[38]	Marsh RA, Hebert K, Kim S, et al. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders[J]. J Allergy Clin Immunol, 2021 Aug 8;S0091-6749(21)01205-7. doi: 10.1016/j.jaci.2021.07.031.Onlineaheadofprint.
[39]	Lehmberg K, Moshous D, Booth C. Haematopoietic Stem Cell Transplantation for Primary Haemophagocytic Lymphohistiocytosis[J]. Front Pediatr, 2019, 7: 435. doi: 10.3389/fped.2019.00435
[40]	Fu L, Wang J, Wei N, et al. Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis[J]. Int J Hematol, 2016, 104(5): 628-635. doi: 10.1007/s12185-016-2062-7
[41]	Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab[J]. Pediatr Blood Cancer, 2013, 60(1): 101-109. doi: 10.1002/pbc.24188
[42]	Hege K, Quigg T, Delgado D. Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH[J]. Pediatr Blood Cancer, 2016, 63(2): 361-363. doi: 10.1002/pbc.25782
[43]	Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date[J]. Ther Clin Risk Manag, 2020, 16: 705-714.
[44]	Ohmura SI, Uehara K, Yamabe T, et al. Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide[J]. Mod Rheumatol Case Rep, 2020, 4(2): 202-207. doi: 10.1080/24725625.2020.1741073
[45]	Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis[J]. Am J Hematol, 2006, 81(1): 59-61. doi: 10.1002/ajh.20462